WilmerHale Advises Underwriters in Follow-On Public Offering of Amylyx Pharmaceuticals

WilmerHale Advises Underwriters in Follow-On Public Offering of Amylyx Pharmaceuticals

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
WilmerHale represented the underwriters in the follow-on public offering of 7,697,812 shares of common stock of Amylyx Pharmaceuticals, Inc., a biopharmaceutical company founded with the goal of improving the quality and length of life for patients suffering from neurodegenerative diseases. The shares of common stock were issued at a public offering price of $32.00 per share. The gross proceeds to Amylyx were $246.3 million before deducting underwriting discounts, commissions, and offering expenses. The offering priced on October 6, 2022 and closed on October 11, 2022. The team consisted of Lisa Firenze, Jeffries Oliver-Li, Ryan Brewer, and Molly Nelson, with assistance from Stuart Falber, Bruce Manheim, Colleen Superko, and Heidi Treiber.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel